Thailand-based Mega Lifesciences (BKK: MEGA) has announced an in-licensing agreement with China-based Bio-Thera Solutions (SHA: 688177) for bevacizumab (BAT1706), a biosimilar version of Roche’s (SWX: ROG) Avastin (bevacizumab). According to the agreement, Mega Lifesciences obtains exclusive distribution and marketing rights to the product in Indonesia, while Bio-Thera will handle the development, manufacturing, and commercial supply of the biosimilar.
Bevacizumab Biosimilar: A Human Anti-VEGF Monoclonal Antibody
Bevacizumab is a human anti-VEGF monoclonal antibody (mAb) that was first approved in China in February 2010 and has been included on the National Reimbursement Drug List (NRDL) since 2017. The market-approved indications for bevacizumab include a range of cancers such as non-small cell lung cancer (NSCLC), metastatic colorectal cancer (mCRC), glioblastoma (GBM), renal cell carcinoma, cervical cancer, and ovarian cancer.
Expanding Access to Cancer Treatments in Indonesia
This partnership between Mega Lifesciences and Bio-Thera Solutions aims to expand access to affordable cancer treatments in Indonesia. By securing exclusive rights to distribute and market BAT1706, Mega Lifesciences is poised to enhance the availability of this critical biosimilar for patients in need.-Fineline Info & Tech
